Dry Eye Disease Drug Pipeline Analysis Report 2025

Dry eye disease is a chronic condition in which the eyes fail to produce enough tears or produce poor-quality tears, leading to discomfort and vision issues. It affects approximately 5% to 50% of the global population, driving demand for better therapies. The growing focus on innovative dry eye disease drug candidates and advanced therapeutic products is accelerating research and development. With increasing awareness and improved diagnostic methods, the market is expected to witness significant growth in the coming years. Promising drug pipelines aim to address unmet needs, offering more effective and targeted treatments for dry eye disease.

Report Coverage

The Dry Eye Disease Drug Pipeline Insight Report by the publisher gives comprehensive insights into dry eye disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for dry eye disease. The dry eye disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The dry eye disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with dry eye disease treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to dry eye disease.

Dry Eye Disease Drug Pipeline Outlook

Dry eye disease (DED) is a common condition where the eyes do not produce enough tears, or the tears evaporate too quickly. It occurs due to factors like aging, prolonged screen time, environmental conditions, or underlying health issues. This tear imbalance leads to irritation, redness, blurred vision, and a gritty sensation, impacting eye comfort and visual clarity.

Dry eye disease is managed through artificial tears, lubricating eye drops, and prescription medications like cyclosporine. Lifestyle changes, such as reducing screen time and using humidifiers, help alleviate symptoms. In severe cases, punctal plugs may be used to retain moisture. Regular eye check-ups ensure proper diagnosis and tailored treatment plans for long-term relief and eye health.

Dry Eye Disease Epidemiology

Dry eye disease (DED) is a common ocular condition impacting millions globally. The worldwide prevalence varies between 5% and 50%, depending on the region. In the United States, 38 million individuals are affected, with 1.2 million receiving active treatment. Approximately one-third of adults in the United Kingdom have DED. Over 8 million people in Japan are estimated to have DED, while India reports a prevalence of 18.4% to 54.3%.

Dry Eye Disease - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of dry eye disease drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Biologics
• Peptides
• Gene Therapies
• Lipids and Fatty Acid Derivatives

By Route of Administration

• Oral
• Parenteral
• Others

Dry Eye Disease - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total dry eye disease clinical trials.

Dry Eye Disease - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the dry eye disease pipeline analysis include small molecules, biologics, peptides, gene therapies, and lipids and fatty acid derivatives. The dry eye disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for dry eye disease.

Dry Eye Disease Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the dry eye disease drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed dry eye disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in dry eye disease clinical trials:

• BioTheraVision, Inc.
• Taejoon Pharmaceutical Co., Ltd.
• VivaVision Biotech, Inc.
• Santen Pharmaceutical Co., Ltd.
• Telios Pharma, Inc.
• Bausch & Lomb Incorporated
• BioTissue Holdings, Inc.
• Novaliq GmbH
• Vanda Pharmaceuticals
• AJU Pharm Co., Ltd.
• Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
• Olympic Ophthalmics, Inc.

Dry Eye Disease Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for dry eye disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of dry eye disease drug candidates.

Drug: Miebo

MIEBO® (Perfluorohexyloctane Ophthalmic Solution), developed by Bausch & Lomb Incorporated, is currently being evaluated in a Phase IV trial. The study aims to examine corneal endothelial cell density in dry eye disease (DED) patients over 12 months. MIEBO® is the first prescription eye drop targeting tear evaporation, offering a novel approach to managing DED symptoms effectively.

Drug: TJO-083

TJO-083, sponsored by Taejoon Pharmaceutical Co., Ltd., is undergoing Phase III clinical development for dry eye disease. The study aims to assess the efficacy and safety of TJO-083 compared to Diquafosol ophthalmic sodium solution (3%) over 12 weeks, demonstrating its non-inferiority. The trial is expected to conclude by March 2025, with an estimated enrollment of 288 participants.

Drug: BTV100

BTV100 is an investigational Cevimeline Ophthalmic Solution sponsored by BioTheraVision, Inc. It is a part of a Phase II study, which aims to evaluate the efficacy, safety, and tolerability of BTV100 in subjects with dry eye disease (DED) through repeat dosing. Approximately 120 participants will be randomized across low, mid, and high doses or a placebo, with study completion expected by February 2026.

Reasons To Buy This Report

The Dry Eye Disease Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for dry eye disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into dry eye disease collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Dry Eye Disease - Pipeline Insight Report

• Which companies/institutions are leading the dry eye disease drug development?
• What is the efficacy and safety profile of dry eye disease pipeline drugs?
• Which company is leading the dry eye disease pipeline development activities?
• What is the current dry eye disease commercial assessment?
• What are the opportunities and challenges present in the dry eye disease drug pipeline landscape?
• What is the efficacy and safety profile of dry eye disease pipeline drugs?
• Which company is conducting major trials for dry eye disease drugs?
• Which companies/institutions are involved in dry eye disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in dry eye disease?

This product will be delivered within 3-5 business days.